Effects of the COVID-19 Public Health Emergency on Formal Meetings and User Fee Applications — Questions and Answers

On 26 May 2020 the FDA published this Q&A Guidance for Industry.

This guidance is being issued to address the Coronavirus Disease 2019 (COVID-19) public health emergency. This guidance is being implemented without prior public comment because the Food and Drug Administration (FDA or Agency) has determined that prior public participation for this guidance is not feasible or appropriate (see section 701(h)(1)(C) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 371(h)(1)(C)) and 21 CFR 10.115(g)(2)). This guidance document is being implemented immediately, but it remains subject to comment in accordance with the Agency’s good guidance practices.

Read more online 
Copyright Widler & Schiemann AG 2020. All Rights Reserved. /